Weight loss drugs may be linked to stomach paralysis, other rare but severe issues, study says
Publishing timestamp: 2023-10-05 11:29:41
Summary
A new study suggests that Novo Nordisk's weight loss and diabetes drugs, Wegovy and Ozempic, may be associated with an increased risk of three rare and severe stomach conditions in non-diabetic patients. The study found that these drugs, known as GLP-1s, may cause stomach paralysis, bowel obstruction, and pancreatitis. The risks were higher in patients taking GLP-1s compared to other weight loss medications. The researchers hope that this study will inform healthcare providers and patients about the potential drawbacks of taking these drugs.
Sentiment: NEGATIVE
Tickers: NOVO.B-DK,
Keywords: business news, biotechnology, biotech and pharmaceuticals, pharmaceuticals, business, breaking news, united states, science, health care industry, novo nordisk a/s,